文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

氯唑西林联合磷霉素对比单用氯唑西林治疗甲氧西林敏感金黄色葡萄球菌菌血症:一项随机试验

Cloxacillin plus fosfomycin versus cloxacillin alone for methicillin-susceptible Staphylococcus aureus bacteremia: a randomized trial.
PubMed 文献 · Nat Med · 2023-10-02

这项多中心、开放标签、III-IV期优效性随机临床试验将215例甲氧西林敏感金黄色葡萄球菌菌血症住院成人按1:1随机分组,分别接受氯唑西林联合磷霉素或单用氯唑西林治疗。第7天治疗成功率联合组为79.8%(83/104),单用组为74.5%(82/110),风险差5.3%(95%CI -5.95~16.48)。联合治疗未在第7天取得优于单药治疗的成功率,独立委员会因无效性建议提前终止招募。

要点

  • 第7天治疗成功率联合组79.8% vs 单用组74.5%,风险差5.3%(95%CI -5.95~16.48)。
  • 除第3天持续性菌血症在联合组较少见外,死亡率与不良事件两组相似。
  • 预设中期分析中独立委员会因无效性建议在达到计划366例前停止招募。

核心结论

  • 在甲氧西林敏感金黄色葡萄球菌菌血症中,氯唑西林联合磷霉素第7天治疗成功率未优于单用氯唑西林。
  • 作者认为进一步试验应考虑感染的内在异质性,采用更个体化的方法。

研究设计与样本

  • 多中心、开放标签、III-IV期优效性随机临床试验,按1:1随机分组。
  • 住院成人甲氧西林敏感金黄色葡萄球菌菌血症患者215例随机,105例接受联合治疗、110例接受单药治疗;意向性分析纳入至少接受1天治疗的214例。
  • 联合组给予静脉氯唑西林2 g每4小时一次联合静脉磷霉素3 g每6小时一次,单用组给予静脉氯唑西林2 g每4小时一次,初始7天。
  • 主要终点为第7天治疗成功,由对分组设盲的独立委员会判定,复合标准包括患者存活、快速序贯器官衰竭评估评分稳定或改善、无发热且血培养甲氧西林敏感金黄色葡萄球菌阴性。

主要发现

  • 第7天治疗成功联合组83/104(79.8%)vs 单用组82/110(74.5%),风险差5.3%(95%CI -5.95~16.48)。
  • 第3天持续性菌血症在联合组较少见。
  • 死亡率与不良事件等次要终点两组相似。
  • 预设中期分析中独立委员会因无效性建议在达到计划随机化366例前停止招募。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 预设中期分析中独立委员会因无效性建议在达到计划随机化366例前停止招募。
  • 作者认为进一步试验应考虑感染的内在异质性,采用更个体化的方法。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Treatment failure occurs in about 25% of patients with methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia. We assessed whether cloxacillin plus fosfomycin achieves better treatment success than cloxacillin alone in hospitalized adults with MSSA bacteremia. We conducted a multicenter, open-label, phase III-IV superiority randomized clinical trial. We randomly assigned patients (1:1) to receive 2 g of intravenous cloxacillin alone every 4 h or with 3 g of intravenous fosfomycin every 6 h for the initial 7 days. The primary endpoint was treatment success at day 7, a composite endpoint with the following criteria: patient alive, stable or with improved quick Sequential Organ Failure Assessment score, afebrile and with negative blood cultures for MSSA, adjudicated by an independent committee blinded to treatment allocation. We randomized 215 patients, of whom 105 received cloxacillin plus fosfomycin and 110 received cloxacillin alone. We analyzed the primary endpoint with the intention-to-treat approach in 214 patients who received at least 1 day of treatment. Treatment success at day 7 after randomization was achieved in 83 (79.8%) of 104 patients receiving combination treatment versus 82 (74.5%) of 110 patients receiving monotherapy (risk difference 5.3%; 95% confidence interval (CI), -5.95-16.48). Secondary endpoints, including mortality and adverse events, were similar in the two groups except for persistent bacteremia at day 3, which was less common in the combination arm. In a prespecified interim analysis, the independent committee recommended stopping recruitment for futility prior to meeting the planned randomization of 366 patients. Cloxacillin plus fosfomycin did not achieve better treatment success at day 7 of therapy than cloxacillin alone in MSSA bacteremia. Further trials should consider the intrinsic heterogeneity of the infection by using a more personalized approach. ClinicalTrials.gov registration: NCT03959345 .

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Grillo S, Pujol M, Miró JM, et al. Cloxacillin plus fosfomycin versus cloxacillin alone for methicillin-susceptible Staphylococcus aureus bacteremia: a randomized trial. Nat Med. 2023. PMID: 37783969. doi:10.1038/s41591-023-02569-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。